Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & 3rd Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

 

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

Brain Tumor Clinical Trials

Clinical trials help bring hope, advance treatments, and often improve outcomes, especially for patients who have had recurrence of a tumor known to be aggressive and generally incurable with current therapies.

Clinical trials are scientific studies in which new treatments are tested in patients to determine if they are safe and effective. Johns Hopkins benefits from a long and rich tradition of collaboration between basic scientists and clinical scientists, which allows for efficient advancement of new ideas from the laboratory to patients. We believe that well designed and carefully conducted research will lead us to the next major breakthrough in the treatment of patients with malignant brain tumors.

To qualify for a particular clinical trials, participants must meet a carefully defined set of criteria. Please contact the coordinator for the trial you are interested in to see if you qualify.

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Contact: Michaella Iacoboni, RN (410-955-8837 or msheeh13@jhmi.edu)
Principle Investigator: Dr. Chetan Bettegowda
Objective: To find out how well AXL inhibitor BGB324 works in treating participants who are undergoing surgery for glioblastoma that has come back 
Eligibility Criteria: Adults under going surgery for  glioblastoma (GBM) that has come back

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

Contact: Michaella Iacoboni, RN (410-955-8837 or msheeh13@jhmi.edu)
Principle Investigator: Dr. Karisa Schreck
Objective: To find out how well encorafenib and binimetinib work in treating recurrent high-grade primary brain tumors.
Eligibility Criteria: Adults with high-grade tumors with BRAF-V600 E or K mutation

Phase I Study of Neoadjuvant GMCI plus Immune Checkpoint Inhibitor Combined with Standard of Care for Newly Diagnosed High-Grade Gliomas (IRB00172749)

Contact: Michaella Iacoboni (msheeh13@jhmi.edu)
Principle Investigator: Dr. Chetan Bettegowda
Objective: To test the safety of a treatment called Gene Mediated Cytotoxic Immunotherapy (GMCI) plus the anticancer drug nivolumab, in combination with standard radiation therapy (RT) + temozolomide (TMZ).
Eligibility Criteria: Adults with a newly diagnosed brain tumor called high grade glioma

A Phase I Trial of anti-Tim-3 in combination with anti-PD-1 and SRS in Recurrent GBM (IRB00104226)

Contact: Kelly Szajna, RN, BSN (410-502-4081)
Principle Investigator: Dr. Lawrence Kleinberg
Objective: To find out if two study drugs PDR001 and MBG453 are safe to give with stereotactic radiosurgery (SRS).
Eligibility Criteria: Adults with recurrent glioblastoma (GBM)

Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas (IRB00151324)

Contact: Amber Michalik (410-502-0756)
Principle Investigator: Dr. Chetan Bettegowda
Objective: To test any good and bad effects of the study drugs called vemurafenib and cobimetinib
Eligibility Criteria: Adults with a craniopharyngioma which has recurred (came back).

Stereotactic Radiosurgery combined with Nivolumab in Patients with Newly Diagnosed Melanoma Metastases in the Brain and Spine (IRB00086553)

Contact: Whitney Isennock (410-955-7008) or Kelly Szajna (410-502-4081)
Principle Investigator: Dr. Lawrence Kleinberg
Objective: To look at the safety of using stereotactic radiosurgery (SRS) and Nivolumab together to treat melanoma that has spread to the brain or spine.
Eligibility Criteria: Adults with newly identified brain OR spinal metastases

Stereotactic Radiosurgery with Nivolumab in Subjects with Chordoma (IRB00117650)

Contact: Whitney Isennock (410-955-7008) or Kelly Szajna (410-502-4081)
Principle Investigator: Dr. Lawrence Kleinberg
Objective: To look at the safety of using Nivolumab alone or Nivolumab and stereotactic radiosurgery (SRS) together to treat advanced chordomas.
Eligibility Criteria: Advanced/recurrent Chordoma in 1 or more site

Malignant Brain Tumor Clinical Trials: What You Need to Know

Johns Hopkins neurosurgeon Chetan Bettegowda discusses when clinical trials are recommended for a patient with a malignant brain tumor, understanding the risks involved and making the decision to participate in a clinical trial.

 

Browse other clinical trials

For a complete list of open clinical trials across Johns Hopkins, visit the database at the Institute for Clinical and Translational Research. You can search by condition, researcher or doctor’s name.

back to top button